

Patient Information

Early Onset Inflammatory Bowel Disease Patient Information

Instructions: Accurate interpretation and reporting of genetic results is contingent upon the reason for testing, clinical information, family history, and ancestry. To help provide the best possible service, supply the information requested below and send paperwork with the specimen, or return by fax to Mayo Clinic Laboratories, Attn: Molecular Technologies Laboratory Genetic Counselors at 507-284-1759. Phone: 800-533-1710 / International clients: +1-507-266-5700 or email MLIINT@mayo.edu

Patient Name (Last, First Middle)		Birth Date (mm-dd-yyyy)	
	ale		
Referring Provider Information			
Referring Provider Name (Last, First)	Phone	Fax*	
Genetic Counselor Name (Last, First)	Phone	Fax*	
*F. Reason for Testing Specify below or attach relevant clinic		hine that complies with applicable HIPAA regulation	
☐ Confirm clinical diagnosis, specify diagnosis: ☐ Family history**, describe: ☐ Other, specify: ☐			
**Genetic testing should be performed on an affected family r Testing should be ordered when there is a previous positive	·	<u> </u>	
Clinical Findings			
□ Crohn's Disease□ Inflammatory Bowel Disease – Uncla□ Other, specify:	ssified Ulcerative Colitis	Age of onset:	
☐ Malabsorption☐ Celiac disease	☐ Endocrine abnormaliti	es, describe:	
☐ Sclerosing cholangitis	☐ Failure to thrive		
☐ Other gastrointestinal symptoms/disorders, describe:	☐ Fever (recurrent)		
	_ ☐ Hepatosplenomegaly		
☐ Arthritis/Arthralgias	☐ Skin, hair, dental, or nail findings, describe:		
Autoimmune disorder(s), describe:			
	_ Uveitis		
Enteropathy, describe:	_ □ Veno-occlusive disease		
Infectious Disease History			
\square Recurrent or difficult to treat infections: \square Viral \square Bac	terial 🗆 Fungal		
☐ Recurrent deep abscesses of the organs or skin			
☐ Gastrointestinal infections			
☐ Other infection, specify:			
On immunoglobulin replacement			

Early Onset Inflammatory Bowel Disease Patient Information (continued)

Patient Name (Last, First Middle)	Birth Date (mm-dd-yyyy)			
Laboratory Findings				
☐ Fecal Calprotectin: ☐ Normal ☐ Increased	'			
\square IgA class antigliadin antibodies: \square Present \square Absent				
\square IgA class antitransglutaminase antibodies (tTGA): \square Present \square Absent				
\square IgA class endomysial antibodies: \square Present \square Absent				
$\ \square$ Abnormal lymphocyte (T-, B-, and NK-cell) subset quantitation; describe or attach report	:			
Humoral markers:				
☐ Abnormal B-cell function (vaccine antibody responses)				
\square Autoantibodies present, specify:				
☐ Immunoglobulins:				
☐ IgG: ☐ Increased ☐ Decreased				
☐ IgG1: ☐ Increased ☐ Decreased ☐ IgG3: ☐ Increased				
☐ IgG2: ☐ Increased ☐ Decreased ☐ IgG4: ☐ Increased	☐ Decreased			
☐ IgA: ☐ Increased ☐ Decreased				
☐ IgM: ☐ Increased ☐ Decreased				
☐ IgD: ☐ Increased ☐ Decreased				
☐ IgE: ☐ Increased ☐ Decreased				
Cellular markers:				
Abnormal TREC assay (eg, newborn screening)	<u> </u>			
☐ Abnormal T-cell function: ☐ Mitogens ☐ Antigens ☐ Anti-CD3 ☐ Anti-CD	D3/CD28			
☐ T-cell subsets:				
□ Naive: □ Increased □ Decreased □ Activated: □ Increas	ed \square Decreased			
☐ Memory: ☐ Increased ☐ Decreased				
□ B-cell subsets:□ Naive:□ Increased□ Decreased□ Marginal zo	and P colley Increased Decreased			
☐ Memory: ☐ Increased ☐ Decreased ☐ Marginal 20	one B-cells: Increased Decreased Decreased			
☐ Switched memory: ☐ Increased ☐ Decreased ☐ Plasmablas				
☐ Oligoclonal T-cells or abnormal TCRVB spectratyping				
☐ Abnormal CD4 T-cell recent thymic emigrants, flow cytometry				
☐ Abnormal haemophilus influenzae B vaccine response				
☐ Abnormal HLA typing for class I or class II HLA antigens				
☐ Abnormal streptococcus pneumoniae IgG antibody response				
Specific protein assay by flow cytometry:				
□ BTK: □ Normal □ Abnormal □ WAS: □ Normal □ Ab	normal			
□ LRBA: □ Normal □ Abnormal □ XIAP: □ Normal □ Ab	normal			
□ DOCK8: □ Normal □ Abnormal □ SAP: □ Normal □ Ab	normal			
☐ Other, specify:				
Blood:				
\square Autoimmune cytopenia \square Eosinophilia \square Lymphocytosis \square Lymphopenia	a 🗆 Thrombocytopenia			
☐ Other hematological abnormality, specify:				
☐ Other laboratory findings, specify:				
☐ If the patient has had GI biopsies, attach a copy of the pathology report.				

Page 2 of 3 MC1235-310rev1223

Early Onset Inflammatory Bowel Disease Patient Information (continued)

Patient Name (Last, First Middle)		Bi	irth Date (mm-dd-yyyy)	
Oncologic History				
☐ Myelodysplasia/AML		Leukemia, specify:		
☐ Lymphoma, specify:	:	☐ Skin cancer, specify:		
☐ Solid tumor, specify:		Other, specify:		
☐ Family history of cancer; specify cancer type and biological relationship to patient:				
Patient Treatment History				
Has the patient received an allogenic stem cell transplant***? No Yes; transplant date (mm-dd-yyyy):				
Is the patient transfusion-dependent***? No Yes; last transfusion date (mm-dd-yyyy): Was this transfusion leukoreduced***? No Yes Unknown				
Chemotherapy: No Yes; date (mm-dd-yyyy):				
***Results may be inaccurate due to the presence of donor DNA if the patient has received an allogeneic hematopoietic stem cell transplant or non-leukocyte reduced blood products. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.				
Family History				
Are there similarly affected relatives? Yes No If "Yes," indicate relationship, and diagnosis or symptoms:				
Have any family member had genetic testing? Yes**** No Unknown ****FMTT / Familial Mutation Targeted Testing should be ordered when there is a previous positive genetic test result in the family. Contact the lab for ordering assistance.				
History of consanguinity: No Yes; relationship details:				
Ancestry				
☐ African/African American ☐ East Asian [☐ Latinx/Latine	☐ South Asian	☐ Unknown	
☐ Ashkenazi Jewish ☐ European ☐	☐ Middle Eastern	\square None of the abov	re Choose not to disclose	

New York State Patients: Informed Consent for Genetic Testing is required. See Informed Consent for Genetic Testing (T576), Informed Consent for Genetic Testing – Spanish (T826), or Informed Consent for Genetic Testing for Deceased Individuals (T782).

Page 3 of 3 MC1235-310rev1223